Germline <i>BRCA</i> Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
Spring Holter(Lunenfeld-Tanenbaum Research Institute), Steven Gallinger(Ontario Institute for Cancer Research), Neesha C. Dhani(Princess Margaret Cancer Centre), Anna Dodd(Princess Margaret Cancer Centre), Malcolm J. Moore(University Health Network), Kara Semotiuk(Lunenfeld-Tanenbaum Research Institute), Ayelet Borgida(Lunenfeld-Tanenbaum Research Institute), Robert C. Grant(Princess Margaret Cancer Centre), Steven A. Narod(Women's College Hospital), Mohammad R. Akbari(University of Toronto), David W. Hedley(Ontario Institute for Cancer Research)
Cited by 396
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k